Dr. Johnny Ngsee’s team has created the first worm model of a genetic form of ALS called ALS8 that can be used to learn more about the disease and test possible therapies. ALS, or Amyotrophic Lateral Sclerosis, is caused by the gradual death of the nerves that control the muscles. There is no prevention or cure, and 80 percent of people with ALS die within two to five years of being diagnosed. Dr. Ngsee’s team created worms with a genetic mutation that mimics the disease.
Members Dr. Ruth Slack and Dr. Ian Graham have been elected by their peers to join the Royal Society of Canada (RSC)
Two of the top researchers in their fields from the University of Ottawa Brain and Mind Research Institute have been announced as recipients of one of the premier accolades in science. Dr. Ruth Slack and Dr. Ian Graham have been elected by their peers to join the Royal Society of Canada (RSC) as Fellows, emblematic of their innovation and renown as the best in their fields. Fellowship includes sitting on panels to advise policy-makers on decisions of great impact such as health care. Already, the two have led advances in patient care in Canada and beyond.
The CNMD is hosting the 4th Ottawa International Conference on Neuromuscular Disease and Biology on September 7-9, 2017. After three previous successful neuromuscular disease conferences in Ottawa, the 2017 conference promises to offer an outstanding program emphasizing recent breakthroughs in basic and translational research and clinical discoveries in neuromuscular disease.
Common acne medication shows promise in treating multiple sclerosis
Clinical trial shows that minocycline, an oral acne medication, can slow the progress of relapsing-remitting MS
A common oral acne medication could provide new, affordable treatment options for Canadians suffering from relapsing-remitting multiple sclerosis, according to the results of a Canadian clinical trial published in the New England Journal of Medicine. The Phase 3 trial showed that minocycline could slow the progress of the disease in people who have recently experienced their first symptoms.